Hepatitis
An Introduction to Hepatitis
Hepatitis represents a substantial health burden worldwide; hepatitis B and hepatitis C combined are among the top four global infectious diseases in terms of mortality. The World Health Organization are aiming for a 90% reduction in hepatitis C by 2030. However, barriers exist, including genetic diversity of the virus, limited models for testing vaccines, and an incomplete understanding of protective immune responses. Recent vaccine research has focussed on adjuvant envelope or core protein and virus-vectored non-structural antigen vaccines. Novel serum markers of infection have enhanced diagnosis, disease staging and monitoring. There have also been advances in antiviral strategies for hepatitis C infection, with several drugs receiving regulatory approval in the past decade.
Our supporting partners do not constitute an endorsement of the content on this page.
Celebrating the next generation of innovators in infectious diseases Following the success of the 2025 Future Leaders, touchINFECTIOUS DISEASES is delighted to launch nominations for the Future Leaders 2026 initiative. The infectious diseases landscape continues to evolve rapidly, driven by emerging pathogens, ...
Positive phase III data from Ionis Pharmaceuticals and GSK plc support bepirovirsen as a potential new treatment for chronic hepatitis B. The global B-Well 1 and B-Well 2 studies met their primary endpoint, demonstrating statistically significant and clinically meaningful functional cure rates compared with standard of care alone. These findings mark a major advance in a field where no approved therapies currently achieve durable functional cure. Full results will be presented at a forthcoming scientific congress and submitted to regulatory authorities worldwide.
Dr Christoph Boesecke presented a study using the Mpox Severity Score system, at the 19th European AIDS Conference (EACS 2025). The Mpox Severity Score system is a tool designed to standardize clinical assessment and improve understanding of disease progression. In this interview, he discusses the system’s clinical relevance, evolving mpox trends since the 2022-2023 outbreaks, and key updates from EACS 2025.
The “PS15 – Co-Chairs’ Choice” session at EACS 2025 gathered a diverse set of late-breaking studies showcasing the most significant and interesting advances in HIV treatment and prevention research presented this year. Curated by session chairs Bruno Spire, Jean-Michel Molina, Karine Lacombe ...
In our inaugural touchINFECTIOUS DISEASES Future Leaders 2025 campaign, we celebrate early-career clinicians and researchers whose innovation, leadership, and curiosity are already shaping better outcomes in patient care, antimicrobial stewardship, and global health.
In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
Despite the availability of curative therapies, hepatitis C virus (HCV) remains a global health challenge.
In this Q&A, you will learn:
- Current HCV treatment standards and remaining barriers to universal access.
- Practical strategies to support adherence and follow-up in underserved groups.
- Key considerations when treating patients with HIV co-infection or cirrhosis.
- The importance of prevention and the role of vaccines in future HCV control.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The US Food and Drug Administration (FDA) has expanded the indication of the pangenotypic direct-acting antiviral (DAA) combination, glecaprevir/pibrentasvir (Mavyret®; AbbVie Inc., North Chicago, IL, USA), to include the treatment of acute hepatitis C virus (HCV) infection in adults ...
The World Vaccine Congress Washington 2025, 21-24 April 2025, delivered another landmark year, bringing together more than 4,000 global stakeholders from biotechnology, pharmaceuticals, government, academia and the broader global health ecosystem. The event reinforced its standing as an influential and collaborative forum in ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
The World Health Organization (WHO) has introduced updated guidelines for managing chronic hepatitis B, with the goal of enhancing testing, diagnosis and treatment, revealed at the 2024 Asian Pacific Conference for the Study of Liver Disease. These guidelines expand recommendations to include teenagers and emphasize patient choice and aim to simplify treatment decisions and improve access to care, particularly in resource-limited areas, by allowing treatment initiation without extensive viral testing.
Despite being the most severe form of viral hepatitis, there is no FDA-approved therapy for chronic hepatitis delta (CHD).1 Patients with CHD can progress to cirrhosis, as early as 5–10 years after infection. Further complications can also develop, such as esophageal ...
Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key ...
A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges ...
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. ...
Dr Marina Klein (McGill University Health Centre, Montreal, Canada) joins touchINFECTIOUS DISEASES to discuss triple elimination of three infections (HIV, HBV and HCV) prevalent in low- and middle-income countries. Dr Klein highlights the challenges of transmission of HIV, hepatitis B ...
The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
